Tirzepatide Reference

GLP-1 / GIP dual agonist · FDA approved

ClassGLP-1 / GIP dual agonist
StatusFDA approved
Typical vials5 mg, 10 mg, 15 mg, 30 mg, 60 mg
Dose range2.5 mg to 15 mg
FrequencyOnce weekly
Half-life~5 days
Dosing unitmilligrams
RouteSubcutaneous injection

What Tirzepatide is

Tirzepatide is a dual agonist of the GLP-1 and GIP receptors, FDA approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. It is the best-characterized compound on this page: dosing, kinetics, and the titration schedule all come straight from the prescribing information.

Commercial products ship as fixed-dose pens. The math below applies to multi-dose vials of lyophilized powder, where you control the concentration with the amount of bacteriostatic water you add.

Reconstitution math

Concentration is everything: the same 10 mg vial gives a different draw for every amount of bacteriostatic water you add. The table uses the common 2 mL setup for each vial size, which puts every unit on a U-100 insulin syringe at 50 mcg for the default vial. Dashes mark draws too small to measure or larger than the syringe.

VialBAC waterConcentration2.5 mg5 mg7.5 mg10 mg12.5 mg15 mg
5 mg2 mL2.5 mg/mL100 u-----
10 mg2 mL5 mg/mL50 u100 u----
15 mg2 mL7.5 mg/mL33.3 u66.7 u100 u---
30 mg2 mL15 mg/mL16.7 u33.3 u50 u66.7 u83.3 u100 u
60 mg2 mL30 mg/mL8.3 u16.7 u25 u33.3 u41.7 u50 u
Tirzepatide syringe drawsDRAW GUIDEEach dose as a filled syringe10 mg vial + 2 mL bacteriostatic water = 0.5 mg per 0.1 mL (10 units).0102030405060708090100units on a U-100 insulin syringe2.5 mg50 u (0.5 mL)5 mg100 u (1 mL)peprecon.com
Draw positions for the common doses at the default setup.

Dosing and protocol

FDA Zepbound titration: 2.5 to 15 mg weekly, four weeks per step.

The labeled schedule starts at 2.5 mg weekly, a dose chosen for tolerability rather than effect, and steps up every four weeks. Each hold gives GI side effects (nausea, early satiety) time to settle before the next step. The labeled maximum is 15 mg weekly.

Tirzepatide titration scheduleDOSINGThe published escalation, step by stepDose per injection (weekly), from the schedule cited below.051015mg15913172125week2.557.51012.515maintenancepeprecon.com
Each step is held before escalating; the final dose continues as maintenance.

Pharmacokinetics

Tirzepatide has published human pharmacokinetics: peak around 24 hours after a subcutaneous dose. The curves below are normalized one-compartment models built from the cited half-life, the same math the Planner uses. They show shape and timing, not absolute blood levels.

Tirzepatide single-dose curvePHARMACOKINETICSOne dose, start to finishRelative level after one subcutaneous dose. Half-life ~5 days; about 97% cleared by 26 days.0%25%50%75%100%0510152025days after injectionpeak ~3 dayshalf of peakpeprecon.com
Tirzepatide accumulation with weekly dosingPHARMACOKINETICSThe same weekly dose builds for weeksRelative level with the same dose every week. Levels stop climbing around week 4.0%25%50%75%100%012345678weeks on the same weekly dosesteady statemarkers = weekly injectionspeprecon.com
Why week-one effects understate the eventual dose: levels build for weeks.

Storage and handling

Lyophilized vials keep best cold, dark, and dry; refrigeration is the community default and freezing lyophilized powder is common for long holds. After reconstitution, refrigerate at 2 to 8 C, do not freeze the solution, and date the vial. Bacteriostatic water's preservative keeps multi-dose use practical for about 28 days by USP convention, though our 120-day stability study found the preservative itself outlasts that window.

The commercial pens are labeled for refrigeration, with a limited room-temperature window (21 days for Zepbound per its labeling). Treat reconstituted vials more conservatively: refrigerate at 2 to 8 C and date the vial the day you mix it.

Got a certificate of analysis with your vial? Run it through our COA Reader: it reads the report in plain English, checks purity and mass against the label claim, and links the testing lab’s own verification page. Our guide to reading a COA explains what the numbers do and do not tell you.

Sources

  1. Zepbound prescribing information (Eli Lilly, 2024)
  2. Furihata et al., Population pharmacokinetics of tirzepatide, Clin Pharmacol Drug Dev 2024 (PMID 38356317)
  3. Jastreboff et al., Tirzepatide once weekly for obesity (SURMOUNT-1), NEJM 2022

Related references: Semaglutide · Retatrutide · Cagrilintide